萬華化學(600309.SH)收漲% Q4業績大超預期
格隆匯3月16日丨昨晚公佈業績的萬華化學(600309.SH)今日收漲3.45%報117.19元,市值3679億元。

公司昨晚公佈業績顯示,2020年全年實現歸母淨利潤100.4億元,同比下降0.87%,但Q4單季度實現歸母淨利潤46.92億元,同比增長86.65%。
機構稱萬華化學Q4業績超預期,主要系Q4下游需求快速恢復,公司MDI產品量價雙升。MDI供給依舊偏緊,加上出口持續向好、國內需求逐步改善,MDI較好景氣度有望維繫,公司成長性也將逐步釋放。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.